Recent Updates
Recently added Catalysts

Telomir Pharmaceuticals, Inc.

TELOFDA catalysts, PDUFA dates & pipeline intelligence
$0.48
▼ -0.01 · -1.96%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full TELO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.4452W HIGH $1.58
Volume
481.51 K
Value Traded
223.47 K
Short % Float
1.02%
Days to Cover
11.9
-15.92%Week
-53.75%1 Month
-55.46%3 Month
-60.57%6 Month
-81.57%5 Year
-81.57%All Time

Cash Data

Unlock TELO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
35.44 M
EPS (TTM)
-0.07
P/E Ratio
-
Ent. Value
30.92 M
Total Shares
73.62 M
Float Shares
73.68 M
Insiders
0.00%
Institutions
4.27%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every TELO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

TELO Catalyst Timeline

Dated clinical, regulatory and corporate events for Telomir Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Telomir Pharmaceuticals, Inc.

53Total events
5Upcoming
1Tier-1 (high impact)
2024 to 2027Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
TELO-MRD
T2Timing Guidance
Subscribe to view catalyst details
TELO-MRD

Event history 43

▲Equity OfferingCorporate
Telomir closes approximately $5.6 million PIPE financing
▲Additional DataTELO-MRDClinical Data
Additional clinical research results comparing blood-based TELO-MRD with bone-marrow NGS (clonoSEQ)
multiple myelomasource ↗
▲PublicationTelomir-1Presentation
Peer-reviewed publication of preclinical data showing Telomir-Zn restores visual function and retinal structure in AMD model
age-related macular degeneration (AMD)source ↗
▲Additional DataTELO-MRDClinical Data
TELO-MRD detected residual myeloma cells in 92.9% of matched samples vs 54.8% by EuroFlow NGF in University of Athens retrospective collaboration
multiple myelomasource ↗
▲Preclinical PoCTelomir-1Preclinical
Telomir-Zn shows inhibition of cell growth in human and canine osteosarcoma models in vitro
osteosarcomasource ↗
▲PublicationTelomir-1Presentation
Peer-reviewed publication of preclinical data for Telomir-Zn
prostate and triple-negative breast cancer (TNBC)source ↗
◆Oral PresentationTelomir-1Presentation
Presentation at BIO International Convention
cancer and agingsource ↗
▲PublicationTelomir-1Presentation
Peer-reviewed publication of preclinical data demonstrating restoration of insulin sensitivity with Telomir-Zn in a diet-induced zebrafish model of T2DM
Type 2 diabetes mellitussource ↗
▲IND ClearanceTelomir-1IND
FDA IND clearance for Phase 1/2 clinical trial in advanced or metastatic triple-negative breast cancer
Triple-negative breast cancersource ↗
▲PublicationTelomir-1Presentation
Peer-reviewed publication of Telomir-Zn preclinical data in Wilson's disease model in Advances in Redox Research
Wilson's diseasesource ↗
Unlock the full TELO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How TELO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-10-06Telomir-1 (Telomir-Zn) Pre-clinical data readout Pre-clinical
Unlock 3 more TELO historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 81%
Micro Cap
(rank 587 of 725)
Percentile Rank
Showing 1 of 1 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Zn-Telomir Small MoleculesNCT07581314Triple-Negative Breast Cancer (TNBC)Phase 1/2 NOT YET_RECRUITING 76Nov 1, 2027
Unlock the TELO pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every TELO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Telomir-1 triple-negative breast cancer2026-01-05statistically significant reductions in primary tumor growth; statistically significant activity on both tumor growth and cancer cell spread; greater tumor growth inhibition than either agent aloneRead MoreTelomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal ModelsRead More
Scroll for more · summaries link to the source press release
Unlock every TELO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock TELO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Aminov ErezDirector, Officer (CEO and Chairman)Grant/Award 1,960,170 1,960,170 held$0.00 05/21/2026
Unlock the full TELO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in TELO for Q3 2026.
Unlock every fund holding TELO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in TELO
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see TELO ownership
Insider and institutional ownership, quarter by quarter.

TELO Short Interest

Shares sold short, counted twice a month.

1.02%
Short % of Float
of tradable shares sold short
750.5K
Shares Sold Short
-2.5% vs prior count
11.9 Very high
Days to Cover
trading days of normal volume to buy every short share back
63.1K
Avg Daily Volume
the average used for days to cover
Unlock TELO short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock TELO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live TELO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock TELO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How TELO ranks across every disease it competes in

Competitive Position is a premium feature
See how TELO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

TELO News

TELO
Oct 6, 2026
TELOPhases

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Telomir Pharmaceuticals has announced a $5.6 million PIPE financing, including a $1 million investment from billionaire John Paul DeJoria. This funding will support the clinical development of Telomir-Zn, which has received FDA clearance for its Phase 1/2 trial targeting advanced or metastatic triple-negative breast cancer. The company aims to use the proceeds to advance its lead program and enhance shareholder value.

Read more →
TELO
Sep 29, 2026
TELOPhases

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Telo Genomics has reported promising results from its TELO-MRD program, which compares blood-based testing for Minimal Residual Disease (MRD) in multiple myeloma patients against traditional bone marrow methods. The study indicates that TELO-MRD detected circulating myeloma cells in a higher percentage of samples than bone marrow tests. However, the findings are preliminary and based on a limited dataset, necessitating further validation before clinical application.

Read more →
TELO
Sep 17, 2026
TELOGeneral

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Telomir Pharmaceuticals announced a peer-reviewed study showing that Telomir-Zn significantly enhances visual function and restores retinal structure in a model of age-related macular degeneration (AMD). The treatment reduced oxidative stress and improved DNA methylation patterns. These findings suggest broader applications for Telomir-Zn beyond its current focus on oncology.

Read more →
TELO
Sep 15, 2026
TELOPhases

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Telo Genomics reported promising clinical research results for its TELO-MRD assay, which detected residual myeloma cells more effectively than traditional bone marrow methods. The assay combines blood-based detection with three-dimensional telomere profiling to assess relapse risk in multiple myeloma patients. While results are encouraging, further validation in larger studies is necessary before commercialization.

Read more →
TELO
Sep 14, 2026
TELOPhases

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Telomir Pharmaceuticals announced promising research from The Ohio State University showing that Telomir-Zn inhibits cell growth in human and canine osteosarcoma models. The study's findings suggest a potential therapeutic opportunity for treating osteosarcoma, which has limited treatment options. The company is also advancing its TNBC program towards Phase 1/2 patient enrollment.

Read more →
TELO
Aug 13, 2026
TELOGeneral

Q2 Quarterly results 2026

Telomir Pharmaceuticals, Inc. (TELO) has released its Q2 quarterly results for 2026. The report is available in both PDF and DOCX formats. Further details regarding the financial performance and operational highlights are expected to be outlined in the report.

Read more →
TELO
Aug 10, 2026
TELOPhases

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Telomir Pharmaceuticals announced a peer-reviewed publication demonstrating that Telomir-Zn suppresses tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models. The study shows that Telomir-Zn effectively targets KDM enzymes by modulating intracellular iron levels, leading to significant anti-cancer activity. The findings support the advancement of Telomir-Zn into a planned Phase 1/2 clinical trial.

Read more →
TELO
Jun 15, 2026
TELOPhases

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Telomir Pharmaceuticals has announced the publication of preclinical data in the journal 'Biomedicine & Pharmacotherapy,' demonstrating that Telomir-Zn restores insulin sensitivity in a zebrafish model of Type 2 diabetes. The study showed significant improvements in glucose metabolism and insulin resistance following 14 days of treatment. This reinforces the evidence supporting Telomir-Zn's mechanism of action geared towards correcting intracellular metal homeostasis, which is implicated in metabolic diseases. The findings contribute to Telomir's development of Telomir-Zn as a therapeutic candidate for conditions such as Type 2 diabetes and triple-negative breast cancer.

Read more →
TELO
May 20, 2026
TELOPhases
▲ +7.4%on this news

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved

Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of data regarding Telomir-Zn, showcasing its effectiveness in improving survival rates and multiple endpoints in a preclinical model of Wilson's disease. The published study highlighted significant benefits, including reduced hepatic copper burden, enhanced liver biomarkers, and improved locomotor function. Importantly, the findings underscore the therapeutic potential of Telomir-Zn in addressing the oxidative stress and mitochondrial dysfunction associated with Wilson's disease. This marks a significant scientific milestone for Telomir, aligning with the ongoing development of their lead program for Triple-Negative Breast Cancer.

Read more →
TELO
Feb 17, 2026
TELOPhases
▲ +5.5%on this news

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Telomir Pharmaceuticals announced promising in vitro data showing that its compound, Telomir-Zn, induces significant tumor cell mortality across various subtypes of triple-negative breast cancer (TNBC). The mechanism is linked to iron modulation, with studies confirming that tumor cell death is iron-dependent. The company is preparing for an Investigational New Drug submission in early 2026, following successful preclinical results.

Read more →
TELO
Feb 5, 2026
TELOGeneral

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Telomir Pharmaceuticals has reported new findings on Telomir-Zn, demonstrating its ability to modulate intracellular metal balance, which is linked to oxidative stress and genomic integrity. The study shows that Telomir-Zn increases zinc levels while reducing redox-active iron, suggesting a novel mechanism for addressing cancer and aging. The company plans to present these findings at several upcoming scientific meetings.

Read more →
TELO
Jan 5, 2026
TELOPhases
▲ +11.2%on this news

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Telomir Pharmaceuticals announced that Telomir-1 showed significant efficacy in reducing tumor growth and metastasis in aggressive triple-negative breast cancer (TNBC) animal models. The study highlighted that Telomir-1, both alone and in combination with paclitaxel, effectively inhibited tumor growth in models with varying chemotherapy responsiveness. These findings underscore the potential for personalized treatment strategies in TNBC.

Read more →
TELO
Aug 12, 2024
TELOGeneral
▲ +15.6%on this news

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Telomir Pharmaceuticals announced the passing of its Chairman and CEO, Dr. Christopher Chapman. In light of this loss, Erez Aminov has been appointed as the new CEO and Chairman. The company also experienced changes in its Board of Directors, with several resignations and new appointments. The leadership transition comes as Telomir continues its focus on developing Telomir-1 for age-related conditions.

Read more →
TELO
Jul 2, 2024
TELOGeneral

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Telomir Pharmaceuticals has been added to the Russell 3000 and Russell Microcap Indexes, effective July 1, 2024. This inclusion highlights the company's growth since its IPO and positions it for further success in developing Telomir-1, a novel treatment aimed at age-related conditions. The Russell indexes are significant benchmarks for investment strategies.

Read more →
TELO
Jun 17, 2024
TELOConferences/Events

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals announced that its scientific advisor, Dr. Adam Kaplin, will participate in a panel at the DIA Global Annual Meeting on June 17, 2024. The panel will focus on the use of generative AI in clinical trials, aiming to improve efficiency and safety in drug development. This opportunity showcases Telomir's commitment to leveraging innovative technologies in its research.

Read more →
TELO
May 30, 2024
TELOPhases
▼ -7.6%on this news· ran to -18% by day 3

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Telomir Pharmaceuticals has initiated pivotal studies for its lead product candidate, Telomir-1, focusing on its safety and efficacy in geriatric canines. The study commenced on May 28, 2024, with initial doses well-tolerated by the animals. This research aims to provide insights into treating age-related conditions, potentially benefiting both pets and humans.

Read more →
TELO
May 16, 2024
TELOGeneral

Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support

Telomir Pharmaceuticals, Inc. has signed a media deal with New to The Street to feature its management in interviews and advertisements aimed at promoting its TELOMIR-1 drug, which targets age-related diseases. This agreement includes broadcasts on Bloomberg TV and the FOX Business Network, alongside digital advertising across New York City. The company is in the pre-clinical stage of developing TELOMIR-1, which aims to reverse age-related inflammation conditions. Management expresses optimism regarding the drug's potential and the increased exposure from the media partnership.

Read more →
TELO
Apr 16, 2024
TELOPhases
▼ -5.3%on this news

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir Pharmaceuticals presented promising pre-clinical data on its age-reversal drug, Telomir-1, at a National Press Club event. The drug showed a 40% increase in telomerase activity and lengthened telomeres in vitro. The company plans to initiate human and animal trials for osteoarthritis in 2025, highlighting its commitment to addressing age-related conditions.

Read more →
TELO
Apr 2, 2024
TELOPhases

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir Pharmaceuticals announced that Dr. Michael F. Roizen will present pre-clinical data for Telomir-1, a drug aimed at reversing age-related conditions, at the National Press Club on April 15, 2024. The data suggests that Telomir-1 may elongate telomeres, potentially stimulating stem cell renewal. The event aims to share findings with the public and the longevity community.

Read more →
TELO
Mar 29, 2024
TELOPhases
▲ +6%on this news· ran to +42% by day 3shared move

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals has partnered with Argenta to conduct a study on Telomir-1's efficacy in treating osteoarthritis in canines. This three to six-month study aims to evaluate the treatment's impact on the disease's progression. The results could also support future human trials for osteoarthritis. The initiative addresses a significant unmet need in canine healthcare.

Read more →

About Telomir Pharmaceuticals, Inc.

Miami, FL 5 employees telomirpharma.com
Headquarters100 SE 2ND ST, MIAMI, FL, 33131
BIOPHARMAWATCH ELITE
Trade the next TELO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime